Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2026)
Assembly Biosciences (ASMB) posted quarterly Current Deferred Revenue of $29.1 million for Q1 2026, down 28.77% year-over-year from $40.8 million in Q1 2025, and down 21.21% quarter-over-quarter from $36.9 million in Q4 2025.
Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Assembly Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $29.1 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 28.77% year-over-year to $29.1 million; the TTM figure through Mar 2026 stood at $29.1 million (down 28.77% YoY), while the FY2025 annual figure was $36.9 million, down 1.91% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $29.1 million, down from $36.9 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $86.3 million in Q4 2023, with the low at $2.7 million in Q4 2022.
- The 5-year median for Current Deferred Revenue is $40.8 million (2025), against an average of $45.6 million.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue soared 3057.48% in 2023, then slumped 56.4% in 2024.
- Assembly Biosciences' Current Deferred Revenue stood at $2.7 million in 2022, then jumped by 3057.48% to $86.3 million in 2023, then plunged by 56.4% to $37.6 million in 2024, then dropped by 1.91% to $36.9 million in 2025, then declined by 21.21% to $29.1 million in 2026.
- Business Quant data shows ASMB's Current Deferred Revenue at $29.1 million in Q1 2026, $36.9 million in Q4 2025, and $42.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.30 Mn |
| Mar 31, 2026 | 29.08 Mn |
| Dec 31, 2025 | 36.90 Mn |
| Sep 30, 2025 | 42.36 Mn |
| Jun 30, 2025 | 40.92 Mn |
| Mar 31, 2025 | 40.82 Mn |
| Dec 31, 2024 | 37.62 Mn |
| Sep 30, 2024 | 32.62 Mn |
| Jun 30, 2024 | 71.98 Mn |
| Mar 31, 2024 | 80.51 Mn |
| Dec 31, 2023 | 86.29 Mn |
| Dec 31, 2022 | 2.73 Mn |
| Dec 31, 2021 | 2.73 Mn |
| Sep 30, 2021 | 2.73 Mn |
| Jun 30, 2021 | 8.99 Mn |
| Mar 31, 2021 | 8.99 Mn |
| Dec 31, 2020 | 8.99 Mn |
| Sep 30, 2020 | 8.99 Mn |
| Mar 31, 2020 | 36.04 Mn |
| Dec 31, 2019 | 37.05 Mn |